Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Vaxcyte reported financial results for the quarter ended September 30, 2026.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Vaxcyte reported financial results for the quarter ended September 30, 2026
- Full quarterly results and management commentary are in Exhibit 99.1 accompanying the 8-K
Item EX-99.1 · Exhibit EX-99.1
- OPUS-1 Phase 3 met all primary endpoints across VAX-31’s 31-valent adult program, materially advancing the planned BLA
- VAX-31 showed safety comparable to PCV20 and PCV21, though serotypes 3 and 12F missed the stricter PCV21 noninferiority threshold
- OPUS-2 and OPUS-3 results expected first half 2027, supporting a planned BLA submission in first half 2028
- October financing raised approximately $1.1B net, including 1.50% convertible notes maturing October 2032, lifting pro forma liquidity to approximately $3.4B
- Third-quarter net loss widened to $297.1M from $212.8M, with R&D increasing to $270.3M from $209.9M as Phase 3 and manufacturing spending accelerated
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.